These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 22681253)
1. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism. Bohinc BN; Gesty-Palmer D Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253 [TBL] [Abstract][Full Text] [Related]
2. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Gesty-Palmer D; Luttrell LM Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957 [TBL] [Abstract][Full Text] [Related]
3. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption. Bohinc BN; Gesty-Palmer D Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967 [TBL] [Abstract][Full Text] [Related]
5. Translating in vitro ligand bias into in vivo efficacy. Luttrell LM; Maudsley S; Gesty-Palmer D Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495 [TBL] [Abstract][Full Text] [Related]
6. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM Sci Transl Med; 2009 Oct; 1(1):1ra1. PubMed ID: 20368153 [TBL] [Abstract][Full Text] [Related]
7. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity. Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189 [TBL] [Abstract][Full Text] [Related]
8. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578 [TBL] [Abstract][Full Text] [Related]
9. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939 [TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. Cupp ME; Nayak SK; Adem AS; Thomsen WJ J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330 [TBL] [Abstract][Full Text] [Related]
11. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089 [TBL] [Abstract][Full Text] [Related]
14. Retromer in Osteoblasts Interacts With Protein Phosphatase 1 Regulator Subunit 14C, Terminates Parathyroid Hormone's Signaling, and Promotes Its Catabolic Response. Xiong L; Xia WF; Tang FL; Pan JX; Mei L; Xiong WC EBioMedicine; 2016 Jul; 9():45-60. PubMed ID: 27333042 [TBL] [Abstract][Full Text] [Related]
15. Delineation of a conserved arrestin-biased signaling repertoire in vivo. Maudsley S; Martin B; Gesty-Palmer D; Cheung H; Johnson C; Patel S; Becker KG; Wood WH; Zhang Y; Lehrmann E; Luttrell LM Mol Pharmacol; 2015 Apr; 87(4):706-17. PubMed ID: 25637603 [TBL] [Abstract][Full Text] [Related]
16. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522 [TBL] [Abstract][Full Text] [Related]
17. Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation. Ferrari SL; Bouxsein ML Sci Transl Med; 2009 Oct; 1(1):1ps1. PubMed ID: 20368152 [TBL] [Abstract][Full Text] [Related]
18. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation. Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486 [TBL] [Abstract][Full Text] [Related]
19. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532 [TBL] [Abstract][Full Text] [Related]
20. Extracellular nucleotides enhance agonist potency at the parathyroid hormone 1 receptor. Kim BH; Pereverzev A; Zhu S; Tong AOM; Dixon SJ; Chidiac P Cell Signal; 2018 Jun; 46():103-112. PubMed ID: 29501726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]